## Correct Answer: A. Misoprostol and Mifepristone At 7 weeks of gestation, medical termination of pregnancy (MTP) is the standard of care in India under the Medical Termination of Pregnancy Act, 2021. The gold-standard regimen is **mifepristone followed by misoprostol**. Mifepristone is a selective progesterone receptor antagonist that blocks progesterone's uterotrophic effects, causing decidual necrosis and cervical softening. It is given as a single 200 mg oral dose. Misoprostol, a synthetic prostaglandin E1 analogue, is administered 36–48 hours later at 400–600 mcg (buccal, sublingual, or vaginal route) to induce uterine contractions and expel the products of conception. This combination achieves success rates of 95–98% when used within 9 weeks of gestation. The sequence is critical: mifepristone must precede misoprostol to sensitize the myometrium and cervix. In India, this regimen is recommended by FOGSI (Federation of Obstetric Gynaecological Societies) and is the most cost-effective, non-invasive approach with minimal complications. At 7 weeks, the patient is well within the window for medical MTP, making this the preferred option over surgical methods. ## Why the other options are wrong **B. Mifepristone and Methotrexate** — Methotrexate is a folate antagonist used historically for early MTP (before 7 weeks) as an alternative to misoprostol, but it is slower-acting, requires multiple doses, and has higher failure rates (70–80%). At 7 weeks, methotrexate is suboptimal and rarely used in modern Indian practice. Misoprostol is superior because it acts within 24–48 hours with higher efficacy. This option represents outdated regimen knowledge. **C. Misoprostol and Medroxyprogesterone** — Medroxyprogesterone is a progestin used for contraception and hormone replacement, not MTP. Using it with misoprostol is illogical because medroxyprogesterone would oppose the abortifacient effect of misoprostol by maintaining progesterone signaling. Mifepristone (not medroxyprogesterone) is the essential progesterone antagonist needed to prime the uterus for misoprostol-induced expulsion. **D. Mifepristone and Medroxyprogesterone** — While mifepristone is correct, medroxyprogesterone is a progestin that would counteract mifepristone's progesterone-blocking effects. Medroxyprogesterone has no role in MTP; it is used for contraception and hormone therapy. Misoprostol is the essential second agent that provides the prostaglandin-mediated uterine contractions needed to complete expulsion after mifepristone sensitizes the endometrium. ## High-Yield Facts - **Mifepristone + misoprostol** is the gold-standard MTP regimen in India for gestations up to 9 weeks; success rate 95–98%. - **Mifepristone 200 mg** is given first (oral, single dose); misoprostol 400–600 mcg follows 36–48 hours later (buccal, sublingual, or vaginal). - **Progesterone antagonism** by mifepristone is essential; it causes decidual necrosis and cervical softening before prostaglandin-induced contractions. - **Medical MTP is preferred over surgical** at 7 weeks in India due to lower cost, non-invasiveness, and FOGSI/government guideline endorsement. - **Medroxyprogesterone is a progestin** (contraceptive/HRT agent), not an abortifacient; it opposes mifepristone and has no role in MTP. ## Mnemonics **MTP Sequence: 'M before M'** **M**ifepristone first (progesterone block), then **M**isoprostol (prostaglandin contraction). Mifepristone primes; misoprostol expels. Use this when choosing between mifepristone-based regimens. **Medroxyprogesterone ≠ MTP** **Medroxyprogesterone** is a **progestin** (contraceptive), not an antagonist. It *maintains* pregnancy, not terminates it. Eliminate any option pairing it with mifepristone or misoprostol. ## NBE Trap NBE pairs mifepristone with methotrexate (Option B) to trap students who confuse historical regimens or conflate different abortifacient mechanisms. Methotrexate was used in older protocols but is now obsolete for MTP in India; misoprostol is the modern, evidence-based partner to mifepristone. ## Clinical Pearl In Indian government hospitals and private clinics, mifepristone + misoprostol is the first-line MTP regimen for all eligible gestations ≤9 weeks because it is affordable, requires no anesthesia, and allows outpatient management—critical for resource-limited settings and rural India where surgical facilities may be distant. _Reference: DC Dutta's Textbook of Obstetrics (8th ed.), Ch. 10 (Medical Termination of Pregnancy); FOGSI Guidelines on MTP, 2021_
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.